Lou L - Search Results

1

Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.

Wang W, Liu Y, Zhao Z, Xie C, Xu Y, Hu Y, Quan H, Lou L. Wang W, et al. Among authors: lou l. Cancer Sci. 2016 Jun;107(6):782-90. doi: 10.1111/cas.12934. Epub 2016 Apr 27. Cancer Sci. 2016. PMID: 27002306 Free PMC article.

2

Three-component, one-pot synthesis of 2,4,5-substituted pyrimidines library for screening against human hepatocellular carcinoma BEL-7402 cells.

Xie F, Li S, Bai D, Lou L, Hu Y. Xie F, et al. Among authors: lou l. J Comb Chem. 2007 Jan-Feb;9(1):12-3. doi: 10.1021/cc060128y. J Comb Chem. 2007. PMID: 17206826 No abstract available.

3

ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein.

Mi Y, Lou L. Mi Y, et al. Among authors: lou l. Br J Cancer. 2007 Oct 8;97(7):934-40. doi: 10.1038/sj.bjc.6603985. Epub 2007 Oct 2. Br J Cancer. 2007. PMID: 17912240 Free PMC article.

4

Anti-tumour clerodane-type diterpenes from Mitrephora thorelii.

Meng DH, Xu YP, Chen WL, Zou J, Lou LG, Zhao WM. Meng DH, et al. J Asian Nat Prod Res. 2007 Sep-Dec;9(6-8):679-84. doi: 10.1080/10286020601103270. J Asian Nat Prod Res. 2007. PMID: 17943565

5

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

Quan H, Xu Y, Lou L. Quan H, et al. Among authors: lou l. Int J Cancer. 2008 Apr 15;122(8):1730-7. doi: 10.1002/ijc.23262. Int J Cancer. 2008. PMID: 18074350

6

Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity.

Xie F, Zhao H, Zhao L, Lou L, Hu Y. Xie F, et al. Among authors: lou l. Bioorg Med Chem Lett. 2009 Jan 1;19(1):275-8. doi: 10.1016/j.bmcl.2008.09.067. Epub 2008 Sep 21. Bioorg Med Chem Lett. 2009. PMID: 19028425

7

1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase.

Quan H, Liu H, Li C, Lou L. Quan H, et al. Among authors: lou l. J Pharmacol Exp Ther. 2009 Jul;330(1):326-33. doi: 10.1124/jpet.109.153320. Epub 2009 Apr 18. J Pharmacol Exp Ther. 2009. PMID: 19377096

8

Synthesis and structure-activity relationship studies of cytotoxic anhydrovinblastine amide derivatives.

Shao Y, Zhang HK, Ding H, Quan HT, Lou LG, Hu LH. Shao Y, et al. J Nat Prod. 2009 Jun;72(6):1170-7. doi: 10.1021/np900157t. J Nat Prod. 2009. PMID: 19499938

9

HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.

Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. Luo H, et al. Among authors: lou l. Leukemia. 2010 Oct;24(10):1807-9. doi: 10.1038/leu.2010.169. Epub 2010 Aug 12. Leukemia. 2010. PMID: 20703259 No abstract available.

10

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. Tian S, et al. Among authors: lou l. Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9. Cancer Sci. 2011. PMID: 21443688 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,056 results

Search Page

Filters